News

CMS is considering coverage for transcatheter aortic valve replacement (TAVR) in patients with aortic regurgitation. This would represent a significant expansion beyond the current approved indication of aortic stenosis.

Digest: CMS coverage for TAVR in aortic regurgitation would open a new market segment and provide reimbursement for an off-label use that has shown feasibility in selected patients but lacks robust trial data.

The FDA approved the Autus Size-Adjustable Valve from Edwards Lifesciences, the first pulmonary valve replacement designed to expand with patient growth, reducing repeat surgeries in pediatric congenital heart disease. The pivotal study of 62 patients aged 18 months to 16 years demonstrated 100% freedom from device-related complications at 30 days, no reinterventions at 6 months, and favorable hemodynamics through 1 year with mean RVOT gradients ≤40 mmHg and less than moderate regurgitation.

Digest: This first-in-class balloon-expandable valve (13-22 mm) with polymeric leaflets addresses a critical unmet need in pediatric congenital valve disease by potentially eliminating multiple open-heart surgeries during childhood growth.

The FDA has approved the first pediatric heart valve prosthesis designed to grow with children as they develop. This represents a significant advancement in congenital valve replacement, potentially reducing the number of reoperations required in pediatric patients.

Digest: This approval addresses a critical unmet need in pediatric structural heart disease by eliminating the requirement for multiple valve replacements as children grow, which could substantially reduce surgical burden and improve long-term outcomes.

The FDA approved the Autus Size-Adjustable Valve, the first surgically implanted pulmonary valve designed to expand with pediatric growth, featuring novel polymeric leaflets rather than bioprosthetic tissue. The valve can be initially implanted at 13mm diameter for toddlers and balloon-expanded up to 22mm as the child matures, potentially reducing the need for multiple open-heart reoperations.

Digest: This landmark approval addresses a significant unmet need in congenital heart disease management and introduces a novel biomaterial approach that could influence future pediatric valve development across multiple positions.

The FDA has granted clearance for a video endoscope system intended for use in select minimally invasive cardiac surgical procedures. Specific procedural indications and device specifications were not detailed in the available content.

Digest: Enhanced visualization technology for minimally invasive cardiac surgery may facilitate adoption of less invasive surgical approaches for structural heart interventions, particularly minimally invasive surgical valve repair and replacement.

The FDA cleared an artificial intelligence tool designed to detect undiagnosed valvular heart disease through analysis of standard 12-lead electrocardiograms. The AI algorithm enables screening for structural heart conditions using routine ECG data without requiring echocardiography.

Digest: This screening tool could facilitate earlier identification of valve disease patients who may be candidates for structural heart interventions, potentially expanding the treatable patient population.

CMS finalized a national coverage determination expanding Medicare coverage for transcatheter aortic valve replacement to include asymptomatic patients with severe aortic stenosis. This represents a significant broadening of the Medicare eligible patient population beyond the previous requirement for symptomatic disease.

Digest: This reimbursement expansion substantially increases the addressable market for TAVR and aligns Medicare coverage with current clinical practice patterns and recent trial evidence in asymptomatic severe AS patients.

The FDA has granted clearance for a new embolic protection device designed to capture debris during transcatheter aortic valve replacement procedures. This device aims to reduce the risk of periprocedural stroke by preventing particulate matter from reaching the cerebral circulation during valve deployment.

Digest: Embolic protection devices address a persistent clinical concern in TAVR, as stroke remains a significant complication affecting 1-3% of procedures and impacting patient outcomes and healthcare costs.

A cardiac surgeon performed the first US implant of an investigational heart valve device that is currently undergoing FDA review but has not yet received regulatory approval. The procedure represents an early access case under what is likely an FDA early feasibility study or expanded access protocol.

Digest: This signals advancement of a novel valve technology through US regulatory pathways and provides early clinical experience that may inform future FDA approval decisions and market adoption strategies.

The TRIC-I-HF trial demonstrated that transcatheter tricuspid valve repair plus optimal medical therapy was superior to medical therapy alone in patients with symptomatic severe tricuspid regurgitation and heart failure. The intervention reduced all-cause death and HF hospitalization with benefits emerging early and sustained to 3 years, along with meaningful quality of life improvements.

Digest: This represents the first time transcatheter tricuspid repair has shown significant reductions in hard clinical endpoints (mortality and HF hospitalization), not just quality of life, potentially establishing a new standard of care for severe tricuspid regurgitation patients.

Ventripoint Diagnostics is expanding subscription-based access to its FDA-cleared VMS+ 4.0 platform, which uses AI and Knowledge Based Reconstruction technology to generate MRI-comparable 3D volumetric measurements of all four cardiac chambers from standard echocardiographic images. The company is implementing a Device-as-a-Service model targeting approximately 80% subscription-based adoption to reduce capital budget barriers for hospital implementation.

Digest: This AI-powered echocardiographic platform addresses a critical need for accurate right ventricular volumetric assessment without requiring MRI, with subscription pricing potentially lowering adoption barriers for structural heart programs evaluating patients for interventions.

The FDA has confirmed a new recall affecting accessories used with Abiomed's Impella percutaneous ventricular assist device system. Specific details regarding the affected accessory components, reason for recall, and adverse event data were not provided in the available article content.

Digest: Impella devices are widely used for hemodynamic support during high-risk PCI and cardiogenic shock management, making any recall of associated accessories clinically relevant for procedural safety and device availability.

The U.S. Department of Justice charged 455 defendants, including 90 physicians and licensed healthcare professionals, with over $6.5 billion in alleged Medicare and Medicaid fraud in a 2026 national enforcement sweep. Healthcare law experts emphasize the need to distinguish between intentional fraud and honest billing mistakes resulting from complex regulatory requirements, as federal investigations continue with CMS deferring over $1 billion in Medicaid payments pending documentation review.

Digest: Heightened federal fraud enforcement and compliance scrutiny may impact structural heart practices through increased billing audits, reimbursement delays, and pressure to document medical necessity for high-cost procedures like TAVR and mitral interventions.

Abbott is collecting real-world data on its TriClip transcatheter tricuspid valve repair system following FDA approval. The post-market data collection will provide insights into clinical outcomes and device performance outside of controlled trial settings.

Digest: Real-world evidence will be critical for understanding TriClip performance in broader patient populations and supporting clinical adoption in the emerging transcatheter tricuspid repair market.

HOPPR launched its fifth AI foundation model, the EF Chest CT Narrative Model, which processes 3D chest CT volumes to generate narrative reports across pulmonary, mediastinal, cardiac, upper abdominal, osseous, and soft tissue regions. The model was trained on a large proprietary U.S. dataset with deliberate overrepresentation of serious conditions including aortic injury, pulmonary embolism, rib fractures, and pneumothorax.

Digest: This AI model offers potential automated assessment of cardiac and aortic anatomy on chest CT, which could support preprocedural planning and screening for structural heart interventions, though clinical validation data were not provided.

ElectroWire Medical received FDA 510(k) clearance for the LightningWire Transseptal Puncture System, a novel electrosurgical guidewire designed to create atrial septal defects for left-sided cardiac procedures. The 0.032-inch diameter system features proprietary insulation enabling low-power transseptal puncture while providing stiffness comparable to 0.035-inch guidewires, with compatibility across existing electrosurgical generators and transseptal introducers.

Digest: This device addresses a critical access step for multiple structural heart procedures including TMVR, LAAO, and atrial fibrillation ablation, potentially improving procedural efficiency and reducing costs through platform-agnostic compatibility.

Medtronic has issued a recall of a heart valve delivery system due to an identified safety risk. Specific details regarding the affected device model, nature of the safety concern, patient impact, and scope of the recall were not provided in the available content.

Digest: Device recalls can impact procedural planning and inventory management for structural heart programs, and may signal potential adverse events requiring vigilance in patients who received the affected system.

CMS has proposed expanding Medicare coverage for transcatheter aortic valve replacement (TAVR) to include asymptomatic patients with severe aortic stenosis. This represents a significant policy shift from current coverage criteria that require symptomatic presentation.

Digest: Expansion of Medicare coverage to asymptomatic severe AS patients could substantially increase the eligible TAVR population and accelerate treatment timing, potentially preventing symptom development and improving outcomes.

The FDA has granted clearance for the first surgical valve specifically designed for tricuspid valve replacement. This represents the first dedicated tricuspid prosthesis approved for surgical implantation, addressing a previously unmet need in tricuspid valve disease management.

Digest: This approval provides cardiac surgeons with a purpose-built solution for tricuspid valve replacement, potentially improving outcomes compared to off-label use of mitral or aortic prostheses in the tricuspid position.

An advocacy group is calling on the Trump administration to change regulations or policies affecting transcatheter aortic valve replacement (TAVR) access, framing the issue as government interference in clinical decision-making. No specific policy changes, clinical data, or patient access barriers are detailed in the available content.

Digest: Potential regulatory or reimbursement policy changes could significantly impact TAVR utilization patterns and patient access, though the specific issues being advocated remain unclear from this brief report.

Boston Scientific invested $1.5 billion in MiRus with an option to acquire its transcatheter aortic valve replacement (TAVR) business. The strategic investment provides Boston Scientific access to MiRus's TAVR platform and optionality in the structural heart valve market.

Digest: This major investment signals Boston Scientific's intent to enter or expand in the TAVR market, potentially reshaping competitive dynamics currently dominated by Edwards and Medtronic.

Cerebral embolic protection devices designed to prevent stroke during transcatheter aortic valve replacement procedures have failed to demonstrate clinical benefit in trials and real-world use. Despite mechanistic rationale and debris capture evidence, these devices have not shown reduction in stroke rates or neurocognitive outcomes, limiting their adoption in routine TAVR practice.

Digest: The lack of clinical efficacy for stroke prevention devices leaves periprocedural stroke as an unresolved complication of TAVR, affecting patient counseling, procedural risk assessment, and development priorities for next-generation protective technologies.

The FDA has approved Medtronic's next-generation mitral valve system for commercial use in the United States. Specific device details, indication, and pivotal trial data supporting the approval were not provided in the article.

Digest: FDA approval of a new mitral valve platform from a major manufacturer expands the structural heart toolset for treating mitral regurgitation and impacts competitive landscape in the rapidly evolving TMVR market.